Salarius Pharmaceuticals Inc.
13F holders, Q4 2025 (December 31)9holders +4
5new positions
1sold out
$0.65avg. 13F price*
At the end of Q4 2025, 9 institutions reported holding Salarius Pharmaceuticals Inc. in their 13F filings, up 4 from Q3 2025. 5 opened new positions and 1 sold out. The largest holders were Warberg Asset Management LLC ($18K), StoneX Group Inc. ($13K) and XTX Topco Ltd ($7K).
- Company
- Salarius Pharmaceuticals Inc.
- CUSIP
- 79400X503
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $48K |
| Exits | 1 | $2K |
All 13F filers, Q3 2025 → Q4 2025: 79,213 shares bought and 500 shares sold, net +78,713 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Warberg Asset Management LLC | 0.06% | New | 28,000 | $18K |
| StoneX Group Inc. | 0.00% | New | 19,992 | $13K |
| XTX Topco Ltd | 0.00% | New | 10,941 | $7K |
| Geode Capital Management, LLC | 0.00% | New | 10,922 | $7K |
| UBS Group AG | 0.00% | Add +16858.6% | 4,918 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 4,437 | $3K |
| Bank of America Corp. | 0.00% | Add +800.0% | 36 | $23 |
| Danske Bank A/S | 0.00% | No change | 1 | $1 |
| Osaic Holdings, Inc. | 0.00% | No change | 3 | $1 |
"% of holder's portfolio" is SALARIUS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Salarius Pharmaceuticals Inc. the manager owns.